Swiss National Bank increased its position in Spark Therapeutics Inc. (NASDAQ:ONCE) by 23.2% during the second quarter, Holdings Channel reports. The institutional investor owned 36,600 shares of the company’s stock after buying an additional 6,900 shares during the period. Swiss National Bank owned about 0.13% of Spark Therapeutics worth $1,871,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of ONCE. Tocqueville Asset Management L.P. increased its position in shares of Spark Therapeutics by 4.1% in the second quarter. Tocqueville Asset Management L.P. now owns 50,650 shares of the company’s stock worth $2,590,000 after buying an additional 2,000 shares in the last quarter. BlackRock Group LTD increased its position in shares of Spark Therapeutics by 92.6% in the first quarter. BlackRock Group LTD now owns 4,843 shares of the company’s stock worth $143,000 after buying an additional 2,328 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Spark Therapeutics during the second quarter worth approximately $124,000. Metropolitan Life Insurance Co. NY increased its position in shares of Spark Therapeutics by 46.0% in the first quarter. Metropolitan Life Insurance Co. NY now owns 7,823 shares of the company’s stock worth $231,000 after buying an additional 2,465 shares in the last quarter. Finally, Capital Fund Management S.A. bought a new position in shares of Spark Therapeutics during the second quarter worth approximately $348,000. Institutional investors and hedge funds own 78.79% of the company’s stock.
Spark Therapeutics Inc. (NASDAQ:ONCE) traded down 1.86% on Thursday, hitting $62.21. 448,330 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $59.04 and its 200-day moving average price is $47.45. Spark Therapeutics Inc. has a 12-month low of $21.20 and a 12-month high of $66.00. The company’s market cap is $1.90 billion.
Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Wednesday, August 10th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by $0.07. The business earned $1.29 million during the quarter, compared to analyst estimates of $1.17 million. Spark Therapeutics had a negative net margin of 366.76% and a negative return on equity of 26.96%. The company’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.60) EPS. Analysts forecast that Spark Therapeutics Inc. will post ($3.96) earnings per share for the current year.
A number of brokerages have commented on ONCE. Jefferies Group restated a “hold” rating on shares of Spark Therapeutics in a research note on Sunday, June 12th. Chardan Capital set a $35.00 target price on shares of Spark Therapeutics and gave the stock a “hold” rating in a research note on Thursday, July 21st. Cantor Fitzgerald restated a “buy” rating on shares of Spark Therapeutics in a research note on Thursday, July 14th. Wedbush restated an “underperform” rating and issued a $29.00 target price (up from $28.00) on shares of Spark Therapeutics in a research note on Wednesday, August 10th. Finally, Zacks Investment Research raised shares of Spark Therapeutics from a “hold” rating to a “buy” rating and set a $66.00 price target for the company in a research report on Thursday, August 11th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and eight have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $62.27.
In other Spark Therapeutics news, Director Hospital Of Philade Children’s sold 1,000,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 16th. The shares were sold at an average price of $60.90, for a total transaction of $60,900,000.00. Following the completion of the transaction, the director now owns 5,768,707 shares in the company, valued at approximately $351,314,256.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jeffrey D. Marrazzo sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, July 18th. The stock was sold at an average price of $52.53, for a total transaction of $262,650.00. Following the transaction, the chief executive officer now owns 235,000 shares of the company’s stock, valued at approximately $12,344,550. The disclosure for this sale can be found here. 9.60% of the stock is currently owned by corporate insiders.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).
Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics Inc. (NASDAQ:ONCE).
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.